Women's Hormonal Condition PCOS Renamed to PMOS in Global Push for Accuracy

Polycystic-ovarian syndrome (PCOS), a condition affecting one in eight women, has been renamed to polyendocrine metabolic ovarian syndrome (PMOS) by an international group of women's health experts. The change, published in The Lancet and presented at the European Congress of Endocrinology in Prague, aims to correct the misconception that the condition is solely about ovarian cysts. In reality, PMOS involves a wider mix of hormonal, metabolic, and ovarian issues.

The term PCOS was deemed 'inaccurate' by experts, as it can lead to delayed diagnosis, fragmented care, and stigma. The new name was chosen in collaboration with 56 academic, clinical, and patient organizations, incorporating input from over 14,000 affected individuals and health professionals worldwide.

PMOS describes the condition's impact on multiple hormones, metabolism, and ovarian function. Symptoms include irregular periods, weight gain, excess hair growth, acne, and fertility challenges. It is also linked to chronic inflammation and insulin resistance. A global implementation strategy is underway to update disease classification, education, and health system alignment.